awmsg logo



atazanavir/cobicistat (Evotaz®)


Reference No. 2629

Publication date:
11/01/2016


Appraisal information

atazanavir/cobicistat (Evotaz®) 300 mg/150 mg film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 04/11/2015
AWMSG meeting date: 09/12/2015
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 4115
Ministerial ratification: 06/01/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Atazanavir/cobicistat (Evotaz®) in combination with other antiretroviral medicinal products is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download